|
|
|
|
|
| Choosing The Right Pharma CMO: The 3 Cs That Matter Most | Article | Ropack Pharma Solutions | Choosing a CMO is a strategic decision that shapes long‑term quality and scalability. Discover how a focused framework helps teams identify partners that can adapt and support growing portfolios. |
|
|
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma | Where CDMOs first flourish, and clinical trials pick up, biotech innovation follows. It has been the China model, and now the addition of biotechs and biotech investment from within and without has South Korea as the new attention-grabbing nation participating throughout our industry. Here's an in-depth analysis from Chief Editor Louis Garguilo. | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
| Innovations In API Manufacturing Of Small Molecule Drugs | White Paper | By Dirk-Jan van Zoelen, Ph.D., Ardena | Read how advances in people, processes, technology, materials, analytics, and sustainability are reshaping small‑molecule API manufacturing to reduce costs, scale efficiently, and meet future demand. |
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
